|
|
 |
|
Viewing report
|
|
|
|
FDA Approves Xarelto (Rivaroxaban) - The First New Oral Anticoagulant Approved to Prevent VTE in Joint Replacement Surgeries in the US
GlobalData, July 2011, Pages: 6
FDA Approves Xarelto (Rivaroxaban) - The First New Oral Anticoagulant Approved to Prevent VTE in Joint Replacement Surgeries in the US
Summary
GlobalData’s report “FDA Approves Xarelto (Rivaroxaban) - The First New Oral Anticoagulant Approved to Prevent VTE in Joint Replacement Surgeries in the US“ provide key insight of the Joint Replacement Surgeries in the US and impact analysis of approval of Rivaroxaban
Scope
The scope of the report includes -
- Impact analysis of the approval of Rivaroxaban first Oral anticoagulant in Joint Replacement Surgeries.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global diabetes market .
- Understanding treatment preferences of physicians in disease state and across treatment flow.
|
|
|
|
